Isabelle Bedgedjian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Isabelle Bedgedjian has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Christiane Mougin
Papillomavirus National Reference Centre, CHU de Besançon, 25000 Besançon, France
2 shared publications - David Guenat
EA 3181, UFR SMP, Université Bourgogne Franche-Comté, LabEx LipSTIC ANR-11-LABX-0021, rue Ambroise Paré, 25000 Besançon, France; Centre National de Référence Papillomavirus, CHU Besançon, Bd Fleming, 25000 Besançon, France
2 shared publications - Didier Riethmuller
Hôpital couple-enfant, CHU Grenoble Alpes, quai Yermoloff, La Tronche 38700, France
2 shared publications - Jean-Luc Prétet
Université Marie et Louis Pasteur, CNRS, Chrono-environnement (UMR 6249), F-25000 Besançon, France; Centre National de Référence Papillomavirus, CHU Besançon, Besançon, France; Laboratoire de biologie cellulaire et moléculaire, CHU Besançon, Besançon, France
2 shared publications - Séverine Valmary-Degano
Service d'Anatomie et cytologie pathologiques, CHU Besançon, Bd Fleming, 25000 Besançon, France; EA 3181, UFR SMP, Université Bourgogne Franche-Comté, LabEx LipSTIC ANR-11-LABX-0021, rue Ambroise Paré, 25000 Besançon, France
2 shared publications - Adrien Chauchet
Department of Hematology, Centre Hospitalier universitaire Lyon Sud, Pierre Benite, France
1 shared publication
Latest Publications
- Open Access
- 10 December 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-13
Down-regulation of A-FABP predicts non-muscle invasive bladder cancer progression: investigation with a long term clinical follow-up
Non-muscle invasive bladder cancers (NMIBC: pTa, pT1) are characterised by a high risk of recurrence and/or progression. Identification of prognostic markers is needed to improve both diagnosis and management of the disease. The aim of this study was to analyse the expression of A-FABP (adipocyte-fatty acid binding protein) and to evaluate its prognostic value in bladder cancer with a long term clinical follow-up. A-FABP expression was investigated by immunohistochemistry in 236 tumours (114 pTa, 61 pT1, 61 pT2–4). Immunostaining was classified as negative (absent or weak immunostaining and moderate or strong staining on ≤10% of cells) or positive (moderate or strong staining on > 10% of cells). Event-free survival (EFS) and overall survival (OS) were determined with a 87.3 months median follow-up in the overall cohort. Recurrence-free survival (RFS) and progression-free survival (PFS) were established in NMIBC. Loss of A-FABP was associated with higher mean age, high stage/grade, and the presence of metastatic lymph nodes. It was correlated with shorter median EFS (17.5 vs 62.5 months; p = 0.001) and mean OS (76.7 vs 154.2 months; p = 0.009) and with higher risk of progression in the pTa/pT1 subgroup (HR, 0.36; 95% CI, 0.13–0.96; p = 0.041) and importantly in the pTa tumours (HR, 0.34; 95% CI, 0.10–0.97; p = 0.045). These results demonstrated that loss of A-FABP expression following a long follow-up was predictive of pTa and pTa/pT1 progression. Immunohistochemistry on diagnostic biopsy is easy to use and could be of value to help clinicians to propose appropriate treatment for these tumours.
- 10 December 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-13
Open AccessDown-regulation of A-FABP predicts non-muscle invasive bladder cancer progression: investigation with a long term clinical follow-up
Non-muscle invasive bladder cancers (NMIBC: pTa, pT1) are characterised by a high risk of recurrence and/or progression. Identification of prognostic markers is needed to improve both diagnosis and management of the disease. The aim of this study was to analyse the expression of A-FABP (adipocyte-fatty acid binding protein) and to evaluate its prognostic value in bladder cancer with a long term clinical follow-up. A-FABP expression was investigated by immunohistochemistry in 236 tumours (114 pTa, 61 pT1, 61 pT2–4). Immunostaining was classified as negative (absent or weak immunostaining and moderate or strong staining on ≤10% of cells) or positive (moderate or strong staining on > 10% of cells). Event-free survival (EFS) and overall survival (OS) were determined with a 87.3 months median follow-up in the overall cohort. Recurrence-free survival (RFS) and progression-free survival (PFS) were established in NMIBC. Loss of A-FABP was associated with higher mean age, high stage/grade, and the presence of metastatic lymph nodes. It was correlated with shorter median EFS (17.5 vs 62.5 months; p = 0.001) and mean OS (76.7 vs 154.2 months; p = 0.009) and with higher risk of progression in the pTa/pT1 subgroup (HR, 0.36; 95% CI, 0.13–0.96; p = 0.041) and importantly in the pTa tumours (HR, 0.34; 95% CI, 0.10–0.97; p = 0.045). These results demonstrated that loss of A-FABP expression following a long follow-up was predictive of pTa and pTa/pT1 progression. Immunohistochemistry on diagnostic biopsy is easy to use and could be of value to help clinicians to propose appropriate treatment for these tumours.
- 1 December 2018
- Published by Elsevier in Journal of Gynecology Obstetrics and Human Reproduction
- Vol. 47 (10) , 525-531
Prevalence and distribution of HPV genotypes and cervical-associated lesions in sexually active young French women following HPV vaccine
- 1 December 2018
- Published by Elsevier in Journal of Gynecology Obstetrics and Human Reproduction
- Vol. 47 (10) , 525-531
Prevalence and distribution of HPV genotypes and cervical-associated lesions in sexually active young French women following HPV vaccine
- 1 December 2015
- Published by Elsevier in Preventive Medicine
- Vol. 81, 157-162
High prevalence of abnormal cervical smears in a hospital cohort of French women beyond the upper age limit screening program
- 1 December 2015
- Published by Elsevier in Preventive Medicine
- Vol. 81, 157-162
High prevalence of abnormal cervical smears in a hospital cohort of French women beyond the upper age limit screening program
- Open Access
- 8 June 2012
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 5 (1) , 27
Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma
Background: Extranodal nasal-type NK/T-cell lymphoma is a rare and severe disease. Considering the rarity of this lymphoma in Europe, we conducted a multicentric retrospective study on nasal-type NK/T cell lymphoma to determine the optimal induction strategy and identify prognostic factors.Methods: Thirty-six adult patients with nasal-type NK/T-cell lymphoma were recruited and assessed. In total, 80 % of patients were classified as having upper aerodigestive tract NK/T-cell lymphoma (UNKTL) and 20 % extra-upper aerodigestive tract NK/T-cell lymphoma (EUNKTL).Results: For advanced-stage disease, chemotherapy alone (CT) was the primary treatment (84 %vs.10 % for combined CT + radiation therapy (RT), respectively), while for early-stage disease, 50 % of patients received the combination of CT + RT and 50 % CT alone. Five-year overall survival (OS) and progression-free survival (PFS) rates were 39 % and 33 %. Complete remission (CR) rates were significantly higher when using CT + RT (90 %)versusCT alone (33 %) (p < 0.0001). For early-stage disease, CR rates were 37 % for CT aloneversus100 % for CT + RT. Quality of response was significantly associated with survival, with 5-year OS being 80 % for CR patientsversus0 % for progressive disease patients (p < 0.01).Conclusion: Early RT concomitantly or sequentially with CT led to improved patient outcomes, with quality of initial response being the most important prognosticator for 5-year OS.
- 8 June 2012
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 5 (1) , 27
Open AccessComplete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma
Background: Extranodal nasal-type NK/T-cell lymphoma is a rare and severe disease. Considering the rarity of this lymphoma in Europe, we conducted a multicentric retrospective study on nasal-type NK/T cell lymphoma to determine the optimal induction strategy and identify prognostic factors.Methods: Thirty-six adult patients with nasal-type NK/T-cell lymphoma were recruited and assessed. In total, 80 % of patients were classified as having upper aerodigestive tract NK/T-cell lymphoma (UNKTL) and 20 % extra-upper aerodigestive tract NK/T-cell lymphoma (EUNKTL).Results: For advanced-stage disease, chemotherapy alone (CT) was the primary treatment (84 %vs.10 % for combined CT + radiation therapy (RT), respectively), while for early-stage disease, 50 % of patients received the combination of CT + RT and 50 % CT alone. Five-year overall survival (OS) and progression-free survival (PFS) rates were 39 % and 33 %. Complete remission (CR) rates were significantly higher when using CT + RT (90 %)versusCT alone (33 %) (p < 0.0001). For early-stage disease, CR rates were 37 % for CT aloneversus100 % for CT + RT. Quality of response was significantly associated with survival, with 5-year OS being 80 % for CR patientsversus0 % for progressive disease patients (p < 0.01).Conclusion: Early RT concomitantly or sequentially with CT led to improved patient outcomes, with quality of initial response being the most important prognosticator for 5-year OS.